Feeling Lucky? try SRNE 觉得幸运吗？试试SRNE

Sorrento Therapeutics, Inc., (SRNE 3.05) a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide.

。SRNE is up nearly 90%  today on 40X average trading volume, this is a show of tremendous interest by investors on this stock.

。SRNE rejected two $3 to $5 per share range buyout offers. SRNE board think this price range is significantly undervalued the company. SRNE believes its immuno-oncology products have short- and long-term value and has said it is in advanced discussions with other biopharmas for collaboration and licensing of its products. Higher take over price offers may be coming in.

。SRNE  owns a 25% equity stake in Celularity, a biopharma start-up created with help from Celgene and United Therapeutics, that's valued at approximately $1 billion. Considering SRNE is only about$220 million, its price can easily double.

。Analysts consensus 1 year price target is $24.50, a near 800% increase from today's price.

。Estimated next year EPS is +60% and average +37% for the next 5 year.

T。echnically, SRNE broke above 200 day moving average at $2.69 and filled gap to $3.2 from end of June 2019. Next resistances are 4 and 6.5. Support is 2.69.

Sorrento Therapeutics，Inc.（SRNE 3.05）是临床阶段的生物技术公司，主要从事发现和开发专注于肿瘤学和全球慢性癌痛治疗的疗法。

。SRNE今天以40倍平均交易量上升了近90％，这表明投资者对该股票表现出极大的兴趣。

。SRNE拒绝了两家公司每股3至5美元的股票收购要求。 SRNE董事会认为该价格范围对公司价值极度低估了。 SRNE认为其免疫肿瘤学产品具有短期和长期价值，并表示正在与其他生物制药公司就其产品的协作和许可进行深入商讨。可能会有更高的收购价格提议。

。SRNE拥有Celularity 25％的股份，Celularity是一家在Celgene和United Therapeutics的帮助下创立的生物制药初创公司，价值约为10亿美元。 而SRNE今天的市值只是2.2亿美元，这可以导致SRNE的股价很容易的翻番。

。分析师综合1年目标价为24.50美元，较当前价格高近近800％。

。估计明年每股收益为+ 60％，未来五年平均为+ 37％。

。技术上，SRNE突破了200日移动平均线2.69美元，并填补了2019年6月底造成的缺口价3.2美元。下一个阻力位是4和6.5美元。支撑位是2.69美元。

NVDA Breaking Out NVDA 正在突破

NVIDIA Corporation （NVDA 212.71） operates as a visual computing company worldwide.The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants.

。On November 14, Nvidia reported Q3 Non-GAAP EPS of $1.78 beats by $0.20; GAAP EPS of $1.45 beats by $0.20. Revenue of $3.01B (-5.3% Y/Y) beats by $90M.

。Bank of America raised price target to 275 from 250. Cowen raised price target to 240 from 195 on November 15.

。Year today gain for NVDA  is 59% compares with AMD's 124%. As the semiconductor sector and most of its stocks and major market indices are making new high,  it is hard to believe that a market darling like NVDA get left behind. NVDA looks have more room to move up.

。Technically, NVDA is breaking out of a 1 month trading range of 200 to 212. Next resistances are 220 then 240. Supports are 206 then 200. CCI is above 0 (a buy signal) and on the verge of breaking above +100 (entering accelerated move up phase) on the daily chart. Price looks clear to 240 on the weekly chart.

NVIDIA Corporation（NVDA 212.71）是一家视觉计算公司服务全球，该公司的产品用于游戏，专业可视化，数据中心和汽车市场。 NVIDIA Corporation将其产品出售给原始设备制造商，原始产品制造商，系统制造商，附加板制造商，零售商/分销商，互联网和云服务提供商，汽车制造商和一级汽车供应商，制图公司，初创企业以及 其他生态系统参与者。


。Nvidia于11月14日公布的第三季度非GAAP每股收益为1.78美元，比去年同期上涨了0.20美元； GAAP每股收益为1.45美元，比去年同期的0.20美元高。营收为$ 3.01B（年同比-5.3％）超过预期$ 90M。

。11月15日美国银行将NVDA目标价从250提升至275。Cowen将目标价格从195提升至240。

。如今，NVDA的年度股价增长为59％，而AMD则为增长124％。 随着半导体行业及其大多数股票和主要市场指数都创下历史新高位，很难相信像NVDA这样的市场宠儿会落伍。 NVDA看起来还有更多的上升空间。

。从技术上讲，NVDA正在突破1个月的交易区间200至212。下一个阻力位是220然后是240。支撑位是206然后是200。在日线图上CCI高于0（买入信号），并即将突破+100（ 进入加速上升阶段）。 从周线图上看，NVDA可清晰升至240。

ROKU Is A Short ROKU 可卖空

Roku, Inc. （122.44）operates a TV streaming platform. The company operates in two segments, Platform and Player. Its platform allows users to discover and access various movies and TV episodes, as well as live sports, music, news, and others. December 31, 2018, the company had 27.1 million active accounts.

。Technicals: ROKU dropped sharply after reporting better than expected earnings and raised this year's outlook. This is a classic sell on news action. The 16% drop on 2.9X average volume generated  downside momentum for the stock near term. The Downside Island Reversal chart pattern also increased its bearish tone. Although it is bouncing up today but the bounce is not likely to last. ROKU has the potential to fill gap down to 100 area. Its resistance are 125 and 50 day moving average at 131.

。ROKU valuation is too high as P/S, P/B, P/C and P/FCF are extremely high at 15, 29, 35 and  2005 respectively and are not likely sustainable.

。Estimated EPS growth for next year is only 20%, a far cry from this year's 86% growth.

。Wedbush rated stock at Neutral on November 7 with price target at 105. Analysts consensus price target is 136.

Roku，Inc.（ROKU 122.44） 经营电视流媒体平台。该公司分为两个部分，平台和播放器。它的平台允许用户发现和访问各种电影和电视剧集，以及现场体育，音乐，新闻等。 2018年12月31日，公司拥有2710万活跃账户。

。技术上ROKU在公布优于预期的业绩并提高了今年的前景后，股价大幅下跌。这是利好消息出来后被抛售的经典行为。 在2.9倍的平均交易量下降了16％为该股带来了下行动力。看跌的岛形逆转图表模式也增加了其看跌基调。尽管今天反弹，但反弹不太可能持续。 ROKU有潜力下跌填补裂口到100。它的阻力是125及50日移动平均线131。

。ROKU的估值过高因为P / S，P / B, P / C及P/FCF分别为极高的15、29，35和2005。它们不太可能可会持续。

。预计明年每股收益增长仅为20％，与今年的86％增长相去甚远。

。Wedbush于11月7日将其股票评级为“中性”，目标价为105。分析师们的共识目标价为136。

QTRX Has Bottomed QTRX已见底

Quanterix Corporation (QTRX), a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD- 1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. It also develops SP-X instrument that is based on Simoa planar array technology For the measurement of multiplex chemiluminescent immunoassays.

。Technicals: QTRX dropped to October-November low at 19 from July's 36 high and then consolidated between 19 and 22.5 for a month before breaking out today on above average volume. This actions signify a bottom is in place for the the stock. Its trend is up since it has broken above its 20 and 50 day moving averages. Its next resistance is 200 day moving average at 25.22 then 28. Support is between 22 and 22.5.

。Good revenue growth: Q3 Revenue: $14.9M (+41%); product sales: $10.7M (+80%) driven by the launch of its HD-X Analyzer and accelerated adoption of its Simoa technology.

。On November 4， QTRX announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix' proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will allow Siemens Healthineers to begin developing blood-based Nf-L The administration marks yet another significant milestone in Quanterix' mission to provide early detection of disease, measurements for treatment efficacy, and disease progression for neurological disorders. The UmanDiagnostics acquisition allows Quanterix to supply researchers globally with the "best- In-class" Simoa Nf-L assays, while continuing to innovate new digital biomarkers to advance the field of research in diagnostics for neurological disorders.

。Financials：Debt/Equity is only 0.10. Current Ratio is a healthy 5.4.

。Only 22.61 million shares float and can easily pushed up.

。Increasing institution interest, institutions own 72% of QTRX stock.

。Canaccord Genuity re-affirmed Buy rating, target 35. Two analyst rated QTRX Strong Buy and two rated Buy. Analysts consensus target is 34.

生命科学公司Quanterix Corporation（QTRX）在北美，欧洲，中东，非洲和亚太地区开发和销售超灵敏的数字免疫测定平台，该平台可促进生命科学研究和诊断的精确。该公司提供Simoa HD-1仪器，这是一种灵敏的自动多重蛋白检测平台。 SR-X仪器使研究人员能够将Simoa检测技术应用于各种应用，包括直接检测核酸。它还开发了基于Simoa平面阵列技术的SP-X仪器，用于测量多重化学发光免疫测定。

。技术上QTRX从7月份的36高点跌至10-11月份的19低价，然后在19点至22.5点之间盘整了一个月，于今天线上突破交易区间。这些都股票已经触底的显示。由于它已经突破了20天和50天移动平均线，因此其趋势为上升。它的下一个阻力是200日移动平均线水平25.22，然后是28。支撑位在22和22.5之间。

。良好的收入增长：第三季度收入：1,490万美元（+ 41％）；产品销售：推出HD-X分析仪并加速采用Simoa技术推动了1,070万美元的销售（增长80％）。

。11月4日QTRX宣布已与Siemens Healthineers达成许可和供应安排，以采用Quanterix专有的Nf-L抗体，该抗体最近从UmanDiagnostics手中收购。获得Nf-L抗体将使Siemens Healthineers可以开始开发基于血液的Nf-L。这标志着Quanterix使命的另一个重要里程碑，该使命旨在提供疾病的早期发现，治疗效果的测量以及神经系统疾病的疾病进展。通过收购UmanDiagnostics，Quanterix可以为全球研究人员提供“同类最佳”的Simoa Nf-L分析法，同时继续创新新的数字生物标记物，以推进神经系统疾病诊断研究领域。

。财务：债务/股本仅为0.10。流动比率为5.4。

。只有2261万股流通，股价可以轻易被推高。

。机构的参与增加，机构现拥有QTRX股份的72％。

。Canaccord Genuity重申买入评级，目标价为35。两位分析师对QTRX 的评级为强买，另外两位评级为买入。分析师们的共识目标是34。

CARS May Fill Gap Up To 18 CARS 或会填空升至18

Cars.com Inc., (CARS 12.84) through its subsidiaries, operates as a digital automotive marketplace that connects car shoppers with sellers and original equipment manufacturers in the United States. Its Cars.com platform consists of Website and mobile application, including a database of approximately 5 million New and used vehicle listings from US-based dealerships and online-only car sellers.

。Bullish technicals:
    .Broke above 3 month trading range of 8.23 to 12.31.
    .Looks ready to fill gap to 18.
    .Trading above its 20 and 50 day moving averages, trend is up.

。Yesterday CARS overcame not very satisfactory Q3 report (EPS missed by cents, revenue better by $1.86 millions. Stock opened down but reverse  and closed up yesterday and today continues its up trend.

。Good valuation：Book Value is 23.5. Price to Book is only 0.52. Price to Sale is only 1.27

。Good EPS Growth：Estimated EPS growth  for next year is 32% and forward PE is only 6.6.

。Short squeeze candidate: Only 66 million share float, nearly 17% short.

。Analyst upgrade: CFRA upgrade from Hold to Buy. Consensus price target 14.4.

Cars.com Inc.（CARS 12.84）通过其子公司，将美国汽车购买者与卖方和原始设备制造商联系起来作为数字汽车市场运作。其Cars.com平台由网站和移动应用程序组成，包括一个数据库，该数据库包含约500万架来自美国经销商和仅在线汽车销售商的新车和二手车清单。

。看涨的技术指标：
    。突破三个月交易区间8.23至12.31。
    。看起来已经准备好填补缺口到18。
    。价位超过其20和50天移动平均线，趋势上升。

。昨日CARS股价克服了不太令人满意的第三季度报告（每股收益小于预期4美分，收入增加了186万美元。昨日开盘但是反转向上作收, 今天继续升势。

。良好的股值：账面价值是$23.5。价格对帐面价值仅为0.52。价格对销售仅为1.27。

。收益增长良好：预计明年的每股收益增长为32％，前导市盈率仅为6.6。

。逼空候选股：只有6600万股流通股，约17％卖空百分比。

。分析师升级：CFRA从“持有”升级到“购买”。综合共识目标价为14.4。

FLGT Looks Ready To Bring Big Return FLGT 看来会带来大利润

Fulgent Genetics, Inc., (FLGT 12.80) together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves Hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally.

。Great Q3 earning report:
. Record billable tests of 20,697, growing 272% year over year
. Record revenue of $10.3 million, growing 84% year over year
. Gross Margin improves 8.9 percentage points year over year and 5.4 percentage points sequentially; cost per test improves 60% year over year and 15% sequentially
. GAAP income of $1.5 million, or $0.08 per share
. Non-GAAP income of $2.6 million, or $0.14 per share
. Cash flow from operations of positive $3.9 million
. Adjusted EBITDA of $3.0 million

。Next year estimated EPS growth is 205%，estimated next 5 year EPS growth is 32%

。Healthy financial situation：0 debt， Current ratio 12

。Small share float and can easily get push up：only 5.97 million shares

。Increasing institution ownership: Institution own 10% of stock, a 3 month increase of 39%

。Pipper Jaffrey upgrade FLGT from Neutral to Overweight

。Technical: FLGT's big 36% percentage up move today on 8.8 times average volume is indicative of great momentum. It formed a break away gap and is breaking out to all time high after a 2.5 months correction on up trend.  On the weekly chart it formed a Bullish Engulfing pattern and looks ready for the second leg up. Based on Measured Move calculation, its next target is around 16. Supports are 12.4 to 12.85 then 11.

Fulgent Genetics，Inc.（FLGT 12.80）及其子公司提供具有临床可行诊断信息给医生的基因检测服务。其技术平台汇集了数据比较和抑制算法，自适应学习软件，遗传诊断工具以及集成的实验室流程。该公司主要服务医院和医疗机构。它通过内部销售人员以及在美国，加拿大，中华人民共和国和国际上的独立销售代表来销售其测试产品。

。出色的第三季度收益报告：
.创记录的计费测试20,697次，同比增长272％
.收入达到创纪录的1,030万美元，同比增长84％
.毛利率同比提高8.9个百分点，比上一季度提高5.4个百分点；每次测试的费用同比提高60％，比上季度提高15％
. GAAP收入为150万美元，或每股0.08美元
.非GAAP收入为260万美元，或每股0.14美元
.运营现金流为390万美元
.调整后的EBITDA为300万美元

。明年估计每股收益增长205％，估计未来5年每股收益增长32％。

。健康的财务状况：债务为0，流动比率为12

。流通量少，可轻易被推高：只有597万股

。机构持股增加：机构拥有10％的股份，三个月内增加了39％

。PiperJaffray将FLGT评级从中性升级到超重

。技术面：今天，FLGT的交易量达到了平均水平的8.8倍，股价涨幅高达36％，预示着强劲的发展势头。在上涨趋势中经过2.5个月的修正后，今天它形成了一个突破性缺口，并突破到历史最高点。在周线图上，它形成了看涨吞没模式，看来准备并开始第二波上升。以“Measured Move”计算，他的下一个目标约为16。支撑12.4-12.85之间然后11。